Business ❯ Healthcare

Clinical Trials

Drug Development Phase 3 Trials Product Development Regulatory Approvals Phase 2 Trials Phase 3 Studies Drug Approval Duchenne Muscular Dystrophy Pipeline Development Research and Development

Erasca Prices $550 Million Upsized Share Sale as Early ERAS-0015 Data Draw Attention

The company says proceeds will fund research and trials to move ERAS-0015 toward planned combination plus expansion readouts in 2027.

Spain Builds an AI Hub as Big Funding Meets Rising Political and Social Pushback

Abeona Posts $8.7 Million Q1 From ZEVASKYN as Patient Treatments and Sites Expand

Capricor Outlines Daramyocell’s FDA Review and Launch Prep as Distributor Dispute Looms

Axsome Reports 57% Q1 Sales Jump as FDA Clears Auvelity for Alzheimer’s Agitation

AstraZeneca Tops Q1 Forecasts, Reaffirms 2026 Outlook as Oncology Fuels Growth

Boston Scientific Slumps to 52-Week Low After Watchman Trial Jitters and Downgrade

Summit Therapeutics Shares Rally as Ivonescimab Trials Near Q2 Readout

Kynam Trims Syndax Stake With $8.18 Million Q4 Sale Disclosed in SEC Filing

Biofrontera Reports Record 2025 Revenue of $41.7 Million and Best-Ever Q4 at $17.1 Million

Tenon Medical Posts Record 2025 Revenue as SImmetry+ Wins FDA Clearance

Merck Sets $70 Billion Mid-2030s Revenue Goal at JPM Conference as Shares Dip

Eli Lilly Prepares €15 Billion Abivax Offer, Eyes Next Wave of Weight-Loss Drugs

AnaptysBio CMO Trims Stake After Option Exercise as Director Reports Separate Sale

MPM BioImpact Exits MBX, MoonLake, Crinetics in Q3, SEC Filing Shows

Eli Lilly Becomes First Health Care Company Valued at $1 Trillion

Day One to Acquire Mersana in Backloaded Deal Worth Up to $285 Million

Arcutis Turns First Profit on Zoryve Surge, Lifts Outlook as Stock Jumps

Alkermes to Buy Avadel in Up to $2.1 Billion Deal With CVR Tied to Lumryz Expansion

Takeda Strikes $11 Billion-Plus Oncology Deal With Innovent, Pays $1.2 Billion Upfront